154 related articles for article (PubMed ID: 32266771)
1. Successful treatment of a refractory pyoderma gangrenosum with risankizumab.
Burgdorf B; Schlott S; Ivanov IH; Dissemond J
Int Wound J; 2020 Aug; 17(4):1086-1088. PubMed ID: 32266771
[No Abstract] [Full Text] [Related]
2. Infliximab for treatment of pyoderma gangrenosum associated with clinically inactive Crohn's disease. A case report.
Kouklakis G; Moschos J; Leontiadis GI; Kadis S; Mpoumponaris A; Molyvas E; Minopoulos GI
Rom J Gastroenterol; 2005 Dec; 14(4):401-3. PubMed ID: 16400359
[TBL] [Abstract][Full Text] [Related]
3. Treatment of severe recalcitrant pyoderma gangrenosum with ustekinumab.
Low ZM; Mar A
Australas J Dermatol; 2018 May; 59(2):131-134. PubMed ID: 29205260
[TBL] [Abstract][Full Text] [Related]
4. [Infliximab for a girl with refractory pyoderma gangrenosum].
Nozawa T; Hara R; Kinoshita J; Sano F; Miyamae T; Imagawa T; Mori M; Hirokado M; Takahashi K; Inayama Y; Yokota S
Nihon Rinsho Meneki Gakkai Kaishi; 2008 Dec; 31(6):454-9. PubMed ID: 19122376
[TBL] [Abstract][Full Text] [Related]
5. Adalimumab for treatment of pyoderma gangrenosum.
Pomerantz RG; Husni ME; Mody E; Qureshi AA
Br J Dermatol; 2007 Dec; 157(6):1274-5. PubMed ID: 17916198
[No Abstract] [Full Text] [Related]
6. Pyoderma gangrenosum caused by secukinumab successfully treated with risankizumab: a case report and literature review.
Orita A; Hoshina D; Hirosaki K
Clin Exp Dermatol; 2022 Jul; 47(7):1372-1374. PubMed ID: 35298047
[TBL] [Abstract][Full Text] [Related]
7. Refractory pyoderma gangrenosum treated with infliximab in an infant.
Campos-Muñoz L; Conde-Taboada A; Aleo E; Toledano E; López-Bran E
Clin Exp Dermatol; 2014 Apr; 39(3):336-9. PubMed ID: 24635074
[TBL] [Abstract][Full Text] [Related]
8. Peristomal Pyoderma Gangrenosum Responding to Risankizumab.
Weigelt MA; Kirsner RS
Adv Skin Wound Care; 2021 Jun; 34(6):327-329. PubMed ID: 33979822
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment with infliximab of refractory pyoderma gangrenosum in 2 patients with inflammatory bowel diseases.
Cocco A; Angelucci E; Viscido A; Caprilli R
Inflamm Bowel Dis; 2007 Oct; 13(10):1317-9. PubMed ID: 17508417
[No Abstract] [Full Text] [Related]
10. Treatment of refractory pyoderma gangrenosum with intravenous immunoglobulin.
de Zwaan SE; Iland HJ; Damian DL
Australas J Dermatol; 2009 Feb; 50(1):56-9. PubMed ID: 19178495
[TBL] [Abstract][Full Text] [Related]
11. Pyoderma gangrenosum associated with ulcerative colitis: response to infliximab.
López San Román A; Bermejo F; Aldanondo I; Carrera E; Boixeda D; Muñoz Zato E
Rev Esp Enferm Dig; 2004 Jun; 96(6):420-2; 422-4. PubMed ID: 15230672
[TBL] [Abstract][Full Text] [Related]
12. Intravenous immunoglobulin is effective as a sole immunomodulatory agent in pyoderma gangrenosum unresponsive to systemic corticosteroids.
Suchak R; Macedo C; Glover M; Lawlor F
Clin Exp Dermatol; 2007 Mar; 32(2):205-7. PubMed ID: 17342799
[No Abstract] [Full Text] [Related]
13. Refractory pyoderma gangrenosum associated with ulcerative colitis successfully treated with infliximab.
Ueda M; Katoh M; Tanizaki H; Tanioka M; Matsumura Y; Miyachi Y
Dermatol Online J; 2012 Jan; 18(1):12. PubMed ID: 22301049
[TBL] [Abstract][Full Text] [Related]
14. Adalimumab treatment for pyoderma gangrenosum.
Heffernan MP; Anadkat MJ; Smith DI
Arch Dermatol; 2007 Mar; 143(3):306-8. PubMed ID: 17372094
[No Abstract] [Full Text] [Related]
15. Refractory and infected pyoderma gangrenosum in a patient with ulcerative colitis: response to infliximab.
De la Morena F; Martín L; Gisbert JP; Fernández Herrera J; Goiriz R
Inflamm Bowel Dis; 2007 Apr; 13(4):509-10. PubMed ID: 17206663
[No Abstract] [Full Text] [Related]
16. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease.
Regueiro M; Valentine J; Plevy S; Fleisher MR; Lichtenstein GR
Am J Gastroenterol; 2003 Aug; 98(8):1821-6. PubMed ID: 12907338
[TBL] [Abstract][Full Text] [Related]
17. Infliximab as a treatment for recalcitrant pyoderma gangrenosum.
Singh M; Andrew SM; Lear JT
Clin Exp Dermatol; 2004 Mar; 29(2):196-7. PubMed ID: 14987282
[No Abstract] [Full Text] [Related]
18. Pyoderma gangrenosum associated with crohn disease: effect of TNF-alpha blockade with infliximab.
Ljung T; Staun M; Grove O; Fausa O; Vatn MH; Hellström PM
Scand J Gastroenterol; 2002 Sep; 37(9):1108-10. PubMed ID: 12374238
[TBL] [Abstract][Full Text] [Related]
19. Severely recalcitrant pyoderma gangrenosum successfully treated with ustekinumab.
Goldminz AM; Botto NC; Gottlieb AB
J Am Acad Dermatol; 2012 Nov; 67(5):e237-8. PubMed ID: 23062936
[No Abstract] [Full Text] [Related]
20. Successful treatment of therapy-resistant chronic vegetating pyoderma gangrenosum with infliximab (chimeric antitumour necrosis factor antibody).
Jenne L; Sauter B; Thumann P; Hertl M; Schuler G
Br J Dermatol; 2004 Feb; 150(2):380-2. PubMed ID: 14996124
[No Abstract] [Full Text] [Related]
[Next] [New Search]
